COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
Combination therapy of caspofungin and amphotericin B could be a useful treatment option in
invasive fungal disease, but before it can be routinely recommended; carefully controlled and
well-designed randomized clinical trials are needed.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Amphotericin B Caspofungin Echinocandins Liposomal amphotericin B